UALCAN

Home
Tutorial
TCGA
Proteomics
CBTN

Select cancer

Adrenocortical carcinoma

Bladder urothelial carcinoma

Brain lower grade glioma

Breast invasive carcinoma

Cervical squamous cell carcinoma

Cholangiocarcinoma

Colon adenocarcinoma

Esophageal carcinoma

Glioblastoma multiforme

Head and Neck squamous cell carcinoma

Kidney Chromophobe

Kidney renal clear cell carcinoma

Kidney renal papillary cell carcinoma

Acute myeloid leukemia

Liver hepatocellular carcinoma

Lung adenocarcinoma

Lung squamous cell carcinoma

Lymphoid Neoplasm Diffuse Large B-cell Lymphoma

Pancreatic adenocarcinoma

Pheochromocytoma and Paraganglioma

Prostate adenocarcinoma

Ovarian serous cystadenocarcinoma

Rectum adenocarcinoma

Skin Cutaneous Melanoma

Stomach adenocarcinoma

Testicular Germ Cell Tumors

Thyroid carcinoma

Uterine Carcinosarcoma

Uterine corpus endometrial carcinoma

GSEC expression profile based on

HNSC : Head and Neck squamous cell carcinoma

Comparison	Statistical significance
Normal-vs-Primary	9.75441765388518E-43

Genecards
NONCODE
PubMed-Cancer

Show statistics

Hide statistics
Comparison	Statistical significance
Normal-vs-Stage1	1.027867E-04
Normal-vs-Stage2	9.38986520635884E-16
Normal-vs-Stage3	6.01841944002662E-13
Normal-vs-Stage4	2.25588059688318E-37
Stage1-vs-Stage2	5.247322E-01
Stage1-vs-Stage3	1.133111E-02
Stage1-vs-Stage4	2.019238E-01
Stage2-vs-Stage3	8.850309E-03
Stage2-vs-Stage4	2.806554E-01
Stage3-vs-Stage4	2.894908E-02

Genecards
NONCODE
PubMed-Cancer

Show statistics

Hide statistics
Comparison	Statistical significance
Normal-vs-Caucasian	1.25258600460422E-40
Normal-vs-AfricanAmerican	8.43731080683692E-08
Normal-vs-Asian	4.373382E-03
Caucasian-vs-AfricanAmerican	2.132405E-01
Caucasian-vs-Asian	8.464432E-01
AfricanAmerican-vs-Asian	5.720308E-01

Genecards
NONCODE
PubMed-Cancer

Show statistics

Hide statistics
Comparison	Statistical significance
Normal-vs-Male	2.89117699846458E-41
Normal-vs-Female	7.41781622610141E-24
Male-vs-Female	2.415058E-01

Genecards
NONCODE
PubMed-Cancer

Show statistics

Hide statistics
Comparison	Statistical significance
Normal-vs-Age(21-40Yrs)	1.19495222380708E-06
Normal-vs-Age(41-60Yrs)	5.42617937149556E-31
Normal-vs-Age(61-80Yrs)	9.93739934751118E-35
Normal-vs-Age(81-100Yrs)	2.73322945214467E-05
Age(21-40Yrs)-vs-Age(41-60Yrs)	3.893762E-02
Age(21-40Yrs)-vs-Age(61-80Yrs)	6.185301E-02
Age(21-40Yrs)-vs-Age(81-100Yrs)	3.934432E-01
Age(41-60Yrs)-vs-Age(61-80Yrs)	6.800686E-01
Age(41-60Yrs)-vs-Age(81-100Yrs)	6.259762E-01
Age(61-80Yrs)-vs-Age(81-100Yrs)	7.614401E-01

Genecards
NONCODE
PubMed-Cancer

Show statistics

Hide statistics
Comparison	Statistical significance
Normal-vs-Grade1	4.1679498961734E-11
Normal-vs-Grade2	3.93359161074997E-38
Normal-vs-Grade3	2.42330165447031E-21
Normal-vs-Grade4	4.625554E-01
Grade1-vs-Grade2	3.302099E-04
Grade1-vs-Grade3	4.98476763122673E-06
Grade1-vs-Grade4	9.726133E-01
Grade2-vs-Grade3	1.933102E-02
Grade2-vs-Grade4	6.302656E-01
Grade3-vs-Grade4	4.491817E-01

Genecards
NONCODE
PubMed-Cancer

Contact UAB
|
Privacy
|
Terms of Use
|
© 2022 The University of Alabama at Birmingham

UAB is an Equal Opportunity/Affirmative Action Employer committed to fostering a diverse, equitable and family-friendly environment in which all faculty and staff can excel and achieve work/life balance irrespective of race, national origin, age, genetic or family medical history, gender, faith, gender identity and expression as well as sexual orientation. UAB also encourages applications from individuals with disabilities and veterans.